Enhanced survival of grafts genetically endowed with the ability to block CD2 and B7
- Author(s)
- Brady, JL; Yamashita, K; Lew, AM;
- Details
- Publication Year 2001-03-01,Volume 10,Issue #2,Page 175-181
- Journal Title
- CELL TRANSPLANTATION
- Publication Type
- Journal Article
- Abstract
- In a model of transplantation rejection, we have tested whether a graft manipulated to secrete immunomodulators could protect itself from immune destruction. An insulinoma cell line having the NOD genotype but also expressing the neoantigen, SV40 T antigen, was transfected with CTLA4Ig or LFA3Ig to block signals in the co-stimulatory/adhesion pathways. This neoantigen is potent at inducing graft rejection. Secretion of CTLA4Ig and LFA3Ig by transfectants promoted survival of the insulinoma graft in young NOD mice. In immunodeficient mice, cell growth was similar for all transfectants. However, in immunocompetent NOD mice the survival/growth of test grafts was significantly better than that of the controls. Graft survival was enhanced additively, when the two test transfectants were cotransplanted. Endowing the graft the ability to secrete immunomodulators that block individual co-stimulatory/adhesion signals can contribute to transplantation success. Blockade of two signals (CD2 and CD28) in these pathways enhances this success.
- Publisher
- COGNIZANT COMMUNICATION CORP
- Keywords
- T-CELL RESPONSES; ALLOGRAFT SURVIVAL; IN-VITRO; TRANSPLANTATION TOLERANCE; MONOCLONAL-ANTIBODIES; XENOGRAFT SURVIVAL; CARDIAC ALLOGRAFT; ISLET ALLOGRAFTS; CTLA4IG; MICE
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2001-03-01 12:00:00